Clinical Trials Logo

Active Ankylosing Spondylitis clinical trials

View clinical trials related to Active Ankylosing Spondylitis.

Filter by:
  • None
  • Page 1

NCT ID: NCT05814939 Recruiting - Clinical trials for Active Ankylosing Spondylitis

Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

Start date: April 26, 2023
Phase: Phase 2
Study type: Interventional

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.

NCT ID: NCT05407246 Completed - Clinical trials for Active Ankylosing Spondylitis

Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis

Start date: August 5, 2022
Phase: Phase 2
Study type: Interventional

This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study. The study was divided into three stages, including screening period(4-week), treatment period(16-week) and observation period. All subjects need to enter a 28 day (4-week) observation period after stopping hemay005 treatment. Main purpose: The efficacy of hemay005 tablet in the treatment of active ankylosing spondylitis (as) was evaluated by placebo parallel control. Secondary purpose: - To evaluate the safety of oral hemay005 tablets in patients with active as. - To evaluate the population pharmacokinetics of hemay005 tablets in patients with active as.

NCT ID: NCT05212051 Recruiting - Clinical trials for Active Ankylosing Spondylitis

Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS

Start date: December 10, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate preliminary efficacy, safety pharmacokinetic (PK) characteristics, pharmacodynamics (PD) haracteristics and immunogenicity of JS005 at different doses in Chinese patients with active Ankylosing Spondylitis. Treatment difference of JS005 150mg,300mg,450mg vs. placebo in Chinese AS patients in terms of ASAS 20 response rate at Week 16 as well as safety profile will be provided by the study .

NCT ID: NCT04876781 Recruiting - Clinical trials for Active Psoriatic Arthritis

Korean Post-marketing Surveillance for Xeljanz XR

XRPMS
Start date: January 12, 2022
Phase:
Study type: Observational

Xeljanz XR extended-release tablets 11 mg (Tofacitinib citrate) is a drug subject to the risk management plan in accordance with Article 4-1-11 of the "Regulation on Safety of Medicinal Products, etc." in Korea. As part of additional pharmacovigilance activity, this Post-marketing Surveillance (PMS) was planned to evaluate safety and effectiveness of Xeljanz XR under routine clinical practice. At least 200 patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis who were treated with Xeljanz XR will be enrolled about four years.

NCT ID: NCT03357471 Completed - Clinical trials for Active Psoriatic Arthritis

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

Start date: November 3, 2017
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and effectively self-inject Certolizumab Pegol (CZP) using the e-Device and to evaluate the post-use structural integrity of used devices and cassettes via visual examination.